BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Has $105.82 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 43.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 203,401 shares of the medical research company's stock after purchasing an additional 61,710 shares during the quarter. Thermo Fisher Scientific accounts for about 0.6% of BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp's portfolio, making the stock its 27th biggest position. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp owned about 0.05% of Thermo Fisher Scientific worth $105,815,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Barrett & Company Inc. acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $28,000. FPC Investment Advisory Inc. acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $28,000. Missouri Trust & Investment Co acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $29,000. Pillar Financial Advisors LLC acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $29,000. Finally, Endeavor Private Wealth Inc. acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $30,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

TMO traded down $6.95 during trading on Friday, hitting $393.53. The stock had a trading volume of 2,318,052 shares, compared to its average volume of 1,865,469. The company has a 50 day moving average price of $442.54 and a 200-day moving average price of $505.23. The firm has a market cap of $148.56 billion, a price-to-earnings ratio of 23.81, a P/E/G ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific Inc. has a one year low of $390.50 and a one year high of $627.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $0.05. The business had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The firm's quarterly revenue was up .2% on a year-over-year basis. During the same period in the previous year, the company posted $5.11 EPS. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.44%. Thermo Fisher Scientific's payout ratio is 10.09%.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the transaction, the chief executive officer now owns 115,174 shares of the company's stock, valued at approximately $59,506,950.58. The trade was a 7.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president now directly owns 23,167 shares of the company's stock, valued at $9,960,188.31. This trade represents a 1.28% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 14,075 shares of company stock worth $7,305,942. 0.33% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have weighed in on TMO. The Goldman Sachs Group set a $610.00 price target on Thermo Fisher Scientific and gave the stock a "buy" rating in a research report on Wednesday, April 23rd. Robert W. Baird lowered their price target on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Citigroup lowered their price target on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Morgan Stanley boosted their price target on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an "overweight" rating in a research report on Friday, January 31st. Finally, Argus reduced their target price on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research note on Tuesday, April 29th. Four investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $607.43.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.